Accentia at buy by Jefferies

Accentia Biopharmaceuticals Inc. was given a buy rating by Jefferies & Co., Inc. analyst Adam Walsh on news that the company's Biovest subsidiary submitted a formal amendment request to the Food and Drug Administration to use the pivotal phase 3 BiovaxID data on molecular remissions, combined with greater physical examination and CT scan evidence of gross tumor remission, to gain conditional approval. Jefferies believes that if the FDA grants the request, BiovaxID could possibly come to market one year earlier, in the fourth quarter of 2009. Shares of the Tampa, Fla., pharmaceutical company were up 12 cents, or 1.60%, at $7.63 on volume of 16,800 shares versus the three-month running average of 56,145 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.